Science Corporation Plans First Human Implantation of Biohybrid Neural Sensor

Science Corporation, the brain-computer interface company founded by Max Hodak, is moving toward its first human implantation of a biohybrid neural sensor, marking a significant milestone in the development of technology designed to treat neurological conditions. The pea-sized device, which contains 520 electrodes, will be placed on a human brain's surface during already-scheduled surgery, with trials potentially beginning in 2027.

The procedure will be led by Murat Günel, chair of neurosurgery at Yale University, positioning the prestigious medical institution as a key partner in this clinical advancement. This represents a substantial step forward for Science Corporation, which has been developing its biohybrid approach as an alternative to traditional brain-computer interface technology.

What distinguishes Science Corporation's approach from competitors is its fundamental architecture. Rather than inserting wires directly into brain tissue—a method that causes damage and limits bandwidth—the company embeds living neurons derived from stem cells into electronics. These neurons form biological bridges between the device and the brain, with only their axons and dendrites extending into brain tissue while the cell bodies remain housed safely in the implanted device. The company uses optogenetics, a technique that allows neurons to be activated with light, combined with microLEDs and electrodes for stimulating and recording neural activity.

The device could address multiple neurological conditions if successful. One early application involves delivering gentle electrical stimulation to damaged brain or spinal cord cells to encourage healing. The biohybrid architecture theoretically offers significantly higher bandwidth than current state-of-the-art devices while avoiding the tissue damage associated with traditional penetrating electrodes, potentially enabling implants that last longer and function more effectively.

Science Corporation has already demonstrated proof of concept in animal studies. A 2024 research paper described experiments in which mice implanted with biohybrid devices were able to respond to optical stimulation of the implanted neurons, effectively demonstrating that neurons grown outside the body could communicate with brain cells. The company believes this approach is scalable to millions of neurons and could eventually achieve bandwidth comparable to the neural fiber bundle connecting the brain's two hemispheres.

The company is also pursuing parallel technologies to maintain momentum while biohybrid implants undergo development. Science Corporation is working on PRIMA, a retinal implant targeting different neurological applications, which is currently in late-stage clinical trials in Europe with expectations for market approval in 2026. However, researchers emphasize that the biohybrid implant remains in very early stages, with a decade or more likely needed before human trials could begin—suggesting that the upcoming procedure represents an accelerated timeline relative to typical neurotechnology development. The company is also commercializing related assets through neuroscience labs and startups, potentially generating revenue while continuing to advance its core biohybrid technology.